TORONTO, ONTARIO--(Marketwired - Feb. 12, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF) a Phase III company developing the first therapy for patients with septic shock guided by a diagnostic, today announced that it will present at the upcoming 20th International Conference on Advances in Critical Care Nephrology (AKI & CRRT) conference in San Diego, California on February 18, 2015 during an interactive luncheon session.

The session will focus on the topic of endotoxin removal using the Toraymyxin™ column ('PMX"), an update on the EUPHRATES trial and a presentation of up-to-date evidence on the effectiveness of PMX collected from European clinical trials, medical registries and a Japanese national database.

Spectral will also unveil, during an invitation only session, its proprietary hemoperfusion/RRT (renal replacement therapies) machine, which is specifically designed to simplify its treatment for patients with septic shock. The machine is intended for use in acute care settings under the direction of doctors and nurses. The Company expects to secure CE mark, FDA 510K licensing and clearances in the current fiscal year in preparation for the potential commercial launch of its septic shock treatment device, PMX, in 2016.

About Spectral Medical Inc.

Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of endotoxemic septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin, a main trigger of sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study for a medical device in the area of septic shock.

PMX has been approved for therapeutic use in Japan and Europe, and has been used on more than 100,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with septic shock in North America each year, representing a greater than $3 billion market opportunity for Spectral.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT, and on the OTCQX under the symbol EDTXF. For more information please visit

Forward-looking statements

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the commercialization of Spectral's septic shock treatment, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

Contact Information:

Spectral Medical Inc.
Anthony Businskas
Executive Vice President and CFO
416-626-3233 ext. 2200

Ali Mahdavi
Capital Markets & Investor Relations